Eton Pharmaceuticals, Inc.
ETON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $584 | $383 | $349 | $348 |
| - Cash | $37 | $25 | $17 | $15 |
| + Debt | $3 | $31 | $30 | $30 |
| Enterprise Value | $551 | $389 | $362 | $363 |
| Revenue | $22 | $19 | $17 | $12 |
| % Growth | 18.7% | 9.5% | 48.4% | – |
| Gross Profit | $8 | $12 | $10 | $6 |
| % Margin | 35% | 63% | 57.1% | 55.6% |
| EBITDA | $0 | -$0 | $1 | $1 |
| % Margin | 1.2% | -2.5% | 3.1% | 8.4% |
| Net Income | -$2 | -$3 | -$2 | -$1 |
| % Margin | -8.6% | -13.7% | -9.1% | -5.1% |
| EPS Diluted | -0.07 | -0.096 | -0.059 | -0.023 |
| % Growth | 27.2% | -64.3% | -155.5% | – |
| Operating Cash Flow | $12 | $8 | $2 | -$1 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | $12 | $8 | $2 | -$1 |